Linked Life Data

20509125

Source:http://linkedlifedata.com/resource/pubmed/id/20509125

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-5-28
pubmed:abstractText
Erythropoiesis stimulating proteins are approved for chemotherapy-induced anemia. Treatment with ESPs results in an increase in hemoglobin in 60 - 70 % of patients and in a significant reduction in transfusion need. A marked increase in hemoglobin levels usually is associated with an improvement in quality of life. Relevant side effects include an increase in thromboembolic complications and, in case of use in unapproved indications, a minimally increased mortality, which is not seen when ESPs are used in the approved indications. Treatment with ESPs should be initiated at hemoglobin levels < 100 g/l and a target level of 120 g/l should not be exceeded.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0040-5930
pubmed:author
pubmed:issnType
Print
pubmed:volume
67
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
271-6
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Erythropoiesis stimulating proteins for the treatment of anemia in cancer patients].
pubmed:affiliation
Zentrum für Onkologie und Hämatologie, I. Medizinische Abteilung, Wilhelminenspital, Wien.
pubmed:publicationType
Journal Article, English Abstract, Review